{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:03:24Z","timestamp":1782975804051,"version":"3.54.5"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016692","name":"Key Research and Development Program of Ningxia","doi-asserted-by":"publisher","award":["2026\u5e7402016\u5e74"],"award-info":[{"award-number":["2026\u5e7402016\u5e74"]}],"id":[{"id":"10.13039\/100016692","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the clinical characteristics and therapeutic management of myelin oligodendrocyte glycoprotein antibody (MOG-Ab)-related optic neuritis (ON), a rare neurological immune-related adverse event (irAE) associated with the programmed death-1 (PD-1) inhibitor tislelizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We report a retrospective case of a 48-year-old male patient with extensive-stage small cell lung cancer (ES-SCLC) who developed acute bilateral vision loss after receiving the first dose of tislelizumab combined with chemotherapy. After admission to the neurology department and a systematic clinical evaluation, the patient was found to be positive for both MOG-Ab and glial fibrillary acidic protein antibody (GFAP-Ab). He was ultimately diagnosed with MOG-Ab-associated ON with Concurrent GFAP-Ab Positivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Following diagnosis, tislelizumab was promptly discontinued. The patient received high-dose methylprednisolone (1,000\u00a0mg\/d) as initial therapy, followed by sequential tapering combined with rituximab for immunomodulation. This regimen resulted in considerable visual recovery. In subsequent treatment lines, immune checkpoint inhibitors (ICIs) were avoided.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case underscores the potential of PD-1 inhibitors to trigger rare MOG-Ab-associated ON. For such vision-threatening irAEs, early recognition, immediate ICI withdrawal, multidisciplinary collaboration, and aggressive immunosuppressive therapy are essential for reversing neurological impairment and improving outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1834795","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:35:49Z","timestamp":1782970549000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["MOG-Ab-associated optic neuritis with concurrent GFAP-Ab positivity following tislelizumab-based treatment: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Yinghui","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Neurology, General Hospital of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, General Hospital of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Xin","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, General Hospital of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, General Hospital of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, General Hospital of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenna","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, General Hospital of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoxiu","family":"Qi","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, General Hospital of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, General Hospital of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4132","DOI":"10.1007\/s00415-023-11737-8","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges","volume":"270","author":"Al-Ani","year":"2023","journal-title":"J. Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"101944","DOI":"10.1016\/j.smim.2025.101944","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): insights into pathogenesis and biomarkers of prognosis","volume":"78","author":"Andersen","year":"2025","journal-title":"Semin. Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"101491","DOI":"10.1016\/j.ajoc.2022.101491","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis with COVID-19 infection: a case report and literature review","volume":"26","author":"Assavapongpaiboon","year":"2022","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"103044","DOI":"10.1016\/j.msard.2021.103044","article-title":"A comparison of the effects of rituximab versus other immunotherapies for MOG-IgG-associated central nervous system demyelination: a meta-analysis","volume":"53","author":"Bai","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"B5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/imr.13262","article-title":"Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses","volume":"318","author":"Blum","year":"2023","journal-title":"Immunol. Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1136\/pn-2024-004327","article-title":"Neurological complications of immune checkpoint inhibitors: a practical guide","volume":"25","author":"Carr","year":"2025","journal-title":"Pract. Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3760\/cma.j.cn113694-20221020-00779","article-title":"Expert consensus on antibody testing for central nervous system autoimmune diseases 2022","volume":"56","year":"2023","journal-title":"Chin. J. Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s42466-021-00145-w","article-title":"Paraneoplastic encephalomyeloradiculitis with multiple autoantibodies against ITPR-1, GFAP and MOG: case report and literature review","volume":"3","author":"Cirkel","year":"2021","journal-title":"Neurol. Res. Pract."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1137998","DOI":"10.3389\/fneur.2023.1137998","article-title":"Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease","volume":"14","author":"Corbali","year":"2023","journal-title":"Front. Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1678663","DOI":"10.3389\/fphar.2025.1678663","article-title":"Case report: tislelizumab-induced panuveitis: a report of two cases","volume":"16","author":"Ding","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/IIO.0000000000000597","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): mechanisms, syndromes, and management","volume":"66","author":"Dolan","year":"2026","journal-title":"Int. Ophthalmol. Clin."},{"key":"B12","doi-asserted-by":"publisher","first-page":"6811","DOI":"10.1007\/s00415-024-12633-5","article-title":"Clinical characteristics of overlapping syndrome in patients with GFAP-IgG and MOG-IgG: a case series of 8 patients and literature review","volume":"271","author":"Fang","year":"2024","journal-title":"J. Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/ana.24881","article-title":"Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients","volume":"81","author":"Flanagan","year":"2017","journal-title":"Ann. Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nrc.2017.87","article-title":"Small-cell lung cancer: what we know, what we need to know and the path forward","volume":"17","author":"Gazdar","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/ana.24715","article-title":"CTLA4 as immunological checkpoint in the development of multiple sclerosis","volume":"80","author":"Gerdes","year":"2016","journal-title":"Ann. Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e202410524","DOI":"10.5546\/aap.2024-10524.eng","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a pediatric case report","volume":"123","author":"Gutierrez","year":"2025","journal-title":"Arch. Argent. Pediatr."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e16284","DOI":"10.1111\/ene.16284","article-title":"Clinical and neuroimaging phenotypes of autoimmune glial fibrillary acidic protein astrocytopathy: a systematic review and meta-analysis","volume":"31","author":"Hagbohm","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.22608\/apo.2017163442","article-title":"Retinal vein occlusion review","volume":"7","author":"Ip","year":"2018","journal-title":"Asia Pac J. Ophthalmol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3969\/j.issn.1002-0152.2024.12.009","article-title":"Research progress on autoimmune glial fibrillary acidic protein astrocytopathy","volume":"50","author":"Jiajia","year":"2024","journal-title":"Chin. J. Neurol. Psychiatr. Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"806501","DOI":"10.3389\/fonc.2022.806501","article-title":"Case report: neuromyelitis optica after treatment of uveal melanoma with nivolumab and ipilimumab","volume":"12","author":"Khimani","year":"2022","journal-title":"Front. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"5609","DOI":"10.1038\/s41598-023-32748-5","article-title":"Serum proteins for monitoring and predicting visual function in patients with recent optic neuritis","volume":"13","author":"Kim","year":"2023","journal-title":"Sci. Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/WNO.0000000000001772","article-title":"The potential pathogenicity of myelin oligodendrocyte glycoprotein antibodies in the optic pathway","volume":"43","author":"Lerch","year":"2023","journal-title":"J. Neuroophthalmol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1610486","DOI":"10.3389\/fimmu.2025.1610486","article-title":"Clinical characteristics of patients with GFAP-IgG coexisting with AQP4-IgG or MOG-IgG","volume":"16","author":"Li","year":"2025","journal-title":"Front. Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"257","DOI":"10.21147\/j.issn.1000-9604.2024.03.03","article-title":"Tislelizumab in previously treated, locally advanced unresectable\/metastatic microsatellite instability-high\/mismatch repair-deficient solid tumors","volume":"36","author":"Li","year":"2024","journal-title":"Chin. J. Cancer Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3969\/j.issn.1671-6450.2025.03.022","article-title":"Research progress on autoimmune encephalitis overlap syndrome","volume":"24","author":"Liu","year":"2025","journal-title":"J. Difficult Complicat. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"E01473","DOI":"10.3760\/cma.j.cmcr.2022.e01473","article-title":"A case of MOG-IgG-related disease induced by PD-1 inhibitor treatment for malignant melanoma","volume":"1","author":"Liu","year":"2022","journal-title":"China Clin. Case Database"},{"key":"B28","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors","volume":"96","author":"Marini","year":"2021","journal-title":"Neurology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"8538","DOI":"10.3390\/ijms26178538","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: pathophysiology, clinical patterns, and therapeutic challenges of intractable and severe forms","volume":"26","author":"Misu","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41582-025-01141-3","article-title":"Implementation of the 2024 revision of the McDonald criteria for multiple sclerosis","volume":"21","author":"Moccia","year":"2025","journal-title":"Nat. Rev. Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s40425-019-0818-3","article-title":"Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient","volume":"7","author":"Pillonel","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3969\/j.issn.1006-2963.2020.02.002","article-title":"Chinese expert consensus on the diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein immunoglobulin G antibody-associated diseases","volume":"27","author":"Qiu","year":"2020","journal-title":"Chin. J. Neuroimmunol. Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e214038","DOI":"10.1212\/WNL.0000000000214038","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease optic neuritis with venous stasis retinopathy","volume":"105","author":"Saify","year":"2025","journal-title":"Neurology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.3389\/fimmu.2018.02802","article-title":"Autoimmune glial fibrillary acidic protein astrocytopathy: a review of the literature","volume":"9","author":"Shan","year":"2018","journal-title":"Front. Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/1759-7714.13266","article-title":"Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related adverse reactions in the nervous system","volume":"11","author":"Shi","year":"2020","journal-title":"Thorac. Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e52975","DOI":"10.7759\/cureus.52975","article-title":"Blinding optic neuropathy associated with carboplatin therapy: a case report and literature review","volume":"16","author":"Shihadeh","year":"2024","journal-title":"Cureus"},{"key":"B39","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e200249","DOI":"10.1212\/NXI.0000000000200249","article-title":"MOG antibody-associated disease in the setting of metastatic melanoma complicated by immune checkpoint inhibitor use","volume":"11","author":"Syc-Mazurek","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"key":"B41","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10637-021-01154-x","article-title":"Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer","volume":"40","author":"Wang","year":"2022","journal-title":"Invest. New Drugs"},{"key":"B42","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1080\/01676830.2020.1867192","article-title":"Ophthalmic complications of immune checkpoint inhibitors","volume":"41","author":"Wladis","year":"2022","journal-title":"Orbit"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1408928","DOI":"10.3389\/fimmu.2024.1408928","article-title":"First-line treatments for extensive-stage small-cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a China-based cost-effectiveness analysis","volume":"15","author":"Yi","year":"2024","journal-title":"Front. Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12864-023-09306-4","article-title":"Identification of lncRNA, miRNA and mRNA expression profiles and ceRNA networks in small cell lung cancer","volume":"24","author":"Zhang","year":"2023","journal-title":"BMC Genomics"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e70102","DOI":"10.1111\/ene.70102","article-title":"A comparative study of 141 glial fibrillary acidic protein immunoglobulin G positive cases","volume":"32","author":"Zhang","year":"2025","journal-title":"Eur. J. Neurol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3760\/cma.j.cn113694-20240629-00441","article-title":"Anti-myelin oligodendrocyte glycoprotein antibody-associated diseases combined with other neuroimmune antibodies","volume":"58","author":"Zhong","year":"2025","journal-title":"Chin. J. Neurol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1834795\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:35:56Z","timestamp":1782970556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1834795\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":46,"alternative-id":["10.3389\/fphar.2026.1834795"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1834795","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"article-number":"1834795"}}